SPYRE THERAPEUTICS, INC. Cash and Cash Equivalents
SPYRE THERAPEUTICS, INC. (SYRE) had Cash and Cash Equivalents of $162.01 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-04
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $162.01M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $97.19M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $85.72M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $64.90M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $162.01M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $97.19M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $85.72M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $64.90M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $81.66M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $48.49M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $89.42M 10-K · filed 2026-02-19 |
| 2024-09-30 | $71.58M 10-Q/A · filed 2024-11-18 |
| 2024-06-30 | $45.14M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $227.55M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $188.89M 10-K · filed 2026-02-19 |
| 2023-09-30 | $90.59M 10-Q/A · filed 2024-11-18 |
| 2023-06-30 | $235.36M 10-Q/A · filed 2024-11-18 |
| 2023-03-31 | $35.24M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $34.86M 10-K · filed 2025-02-27 |
| 2022-09-30 | $38.99M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $37.47M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $14.64M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $15.14M 10-K · filed 2023-03-02 |
| 2021-09-30 | $24.66M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $34.77M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $80.23M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $90.09M 10-K · filed 2022-03-08 |
| 2020-09-30 | $54.22M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $65.71M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $12.59M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $19.25M 10-K · filed 2021-03-18 |
| 2019-09-30 | $24.55M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $25.43M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $85.64M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $22.46M 10-K · filed 2020-02-24 |
| 2018-09-30 | $14.53M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $20.58M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $10.76M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $12.82M 10-K · filed 2019-03-07 |
| 2017-09-30 | $13.16M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $26.93M 10-Q · filed 2018-08-09 |
| 2017-03-31 | $16.80M 10-Q · filed 2018-05-08 |
| 2016-12-31 | $47.75M 10-Q · filed 2018-08-09 |
| 2016-09-30 | $49.54M 10-Q · filed 2017-11-07 |
| 2016-06-30 | $70.63M 10-Q · filed 2017-08-09 |
| 2016-03-31 | $24.02M 10-Q · filed 2017-05-09 |
| 2015-12-31 | $29.29M 10-K · filed 2018-03-13 |
| 2015-09-30 | $30.84M 10-Q · filed 2016-11-09 |
| 2015-06-30 | $39.08M 10-Q · filed 2016-08-09 |
| 2015-03-31 | $43.79M 10-Q · filed 2016-05-19 |
| 2014-12-31 | $2.62M 10-K · filed 2018-03-13 |
| 2013-12-31 | $4.60M 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |